These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28513462)

  • 1. Invasion and metastasis of tumour cells resistant to chemotherapy.
    Nowakowska A; Tarasiuk J
    Postepy Hig Med Dosw (Online); 2017 May; 71(0):380-397. PubMed ID: 28513462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs.
    Wu K; Bonavida B
    Crit Rev Immunol; 2009; 29(3):241-54. PubMed ID: 19538137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
    Kaye SB
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk in cancer resistance and metastasis.
    Norouzi S; Gorgi Valokala M; Mosaffa F; Zirak MR; Zamani P; Behravan J
    Crit Rev Oncol Hematol; 2018 Dec; 132():145-153. PubMed ID: 30447920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colon cancer: cancer stem cells markers, drug resistance and treatment.
    Kozovska Z; Gabrisova V; Kucerova L
    Biomed Pharmacother; 2014 Oct; 68(8):911-6. PubMed ID: 25458789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer cell fusion: a potential target to tackle drug-resistant and metastatic cancer cells.
    Fernandes C; Prabhu P; Juvale K; Suares D; Yc M
    Drug Discov Today; 2019 Sep; 24(9):1836-1844. PubMed ID: 31163272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining the relationship between cancer invasion/metastasis and drug resistance.
    Liang Y; McDonnell S; Clynes M
    Curr Cancer Drug Targets; 2002 Sep; 2(3):257-77. PubMed ID: 12188911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
    Pérez-Tomás R
    Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells.
    Ren Z; Gu X; Lu B; Chen Y; Chen G; Feng J; Lin J; Zhang Y; Peng H
    J Cell Mol Med; 2016 Jun; 20(6):1095-105. PubMed ID: 26864945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor compound RY10-4 suppresses multidrug resistance in MCF-7/ADR cells by inhibiting PI3K/Akt/NF-κB signaling.
    Yang X; Ding Y; Xiao M; Liu X; Ruan J; Xue P
    Chem Biol Interact; 2017 Dec; 278():22-31. PubMed ID: 28987325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Strategies to Overcome Resistance to Chemotherapy and Immune System in Cancer.
    Riganti C; Contino M
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.
    Dessein AF; Stechly L; Jonckheere N; Dumont P; Monté D; Leteurtre E; Truant S; Pruvot FR; Figeac M; Hebbar M; Lecellier CH; Lesuffleur T; Dessein R; Grard G; Dejonghe MJ; de Launoit Y; Furuichi Y; Prévost G; Porchet N; Gespach C; Huet G
    Cancer Res; 2010 Jun; 70(11):4644-54. PubMed ID: 20460542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance and malignancy in human osteosarcoma.
    Scotlandi K; Serra M; Nicoletti G; Vaccari M; Manara MC; Nini G; Landuzzi L; Colacci A; Bacci G; Bertoni F; Picci P; Campanacci M; Baldini N
    Cancer Res; 1996 May; 56(10):2434-9. PubMed ID: 8625324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.
    Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y
    Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy.
    Ullah MF
    Asian Pac J Cancer Prev; 2008; 9(1):1-6. PubMed ID: 18439063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KiSS1 in regulation of metastasis and response to antitumor drugs.
    Corno C; Perego P
    Drug Resist Updat; 2019 Jan; 42():12-21. PubMed ID: 30776659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism.
    Hakomori S
    Cancer Res; 1996 Dec; 56(23):5309-18. PubMed ID: 8968075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.
    Cheng Y; Tao L; Xu J; Li Q; Yu J; Jin Y; Chen Q; Xu Z; Zou Q; Liu X
    Mol Carcinog; 2014 Sep; 53(9):686-97. PubMed ID: 23681900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.